Side-by-side · Research reference

TriptorelinvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED16/64 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Triptorelin

GnRH Agonist · FDA-Approved

3.75–22.5 mgDepot dose rangeYee 2025 Chen 2024

<50 ng/dLTestosterone target

1–6 monthsDepot durationYee 2025 Chen 2024

IM · Depot Injection · Monthly to 6-MonthlyYee 2025

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Triptorelin

Vesugen

Primary target

Pituitary GnRH receptorsUnknown 2012

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

GnRH receptor agonism → initial flare (LH/FSH spike) → receptor desensitization → sustained LH/FSH suppression

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Castration-level suppression of testosterone (men) and estrogen (women) within 2–4 weeks post-flare

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

No — bypasses physiological pulsatility; continuous agonism produces paradoxical suppression

Not applicable — does not operate via hormone axis

Origin

Synthetic decapeptide analogue of native GnRH with amino acid substitutions for enhanced receptor affinity and stability

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Triptorelin

Vesugen

1-month depot

3.75 mg IM

Most common formulation for prostate cancer.

—

3-month depot

11.25 mg IMYee 2025

Reduced injection frequency.

—

6-month depot

22.5 mg IMYee 2025 Chen 2024

Long-acting formulation; improved adherence in real-world use.Yee 2025

—

Administration route

Intramuscular (IM) — gluteal or deltoid

—

Frequency

Every 1, 3, or 6 months per formulation

Not specified in available literature

Indication: Prostate cancer

Advanced (metastatic or locally advanced)

Androgen deprivation therapy (ADT) backbone.

—

Indication: Endometriosis

3.75 mg monthly

FDA-approved; typically 6-month course.

—

Indication: Central precocious puberty

Pediatric use (≥2 years)Jia 2025

Weight-based dosing per FDA label.

—

Evidence basis

Multiple Phase 3 RCTs · FDA-approved 1999

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration (prostate cancer)

Continuous or intermittent ADT protocolsPreston 2024

Intermittent ADT may reduce side effects; cardiovascular risk similar to continuous.

—

Monitoring

Serum testosterone, PSA (prostate cancer), bone density, lipids, glucose

—

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

Duration

—

Case series report treatment courses in elderly arterial insufficiency

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

04Side Effects & Safety

Parameter

Triptorelin

Vesugen

Initial flare symptoms

Bone pain, urinary obstruction, spinal cord compression (first 2 weeks)

Antiandrogen co-treatment (bicalutamide) mitigates flare in metastatic disease.

—

Cardiovascular events

MI, stroke, arrhythmia — GnRH agonists show higher CV risk vs antagonists in meta-analysesPatel 2025 Preston 2024

—

Hot flashes

Very common (>60%); vasomotor instability

—

Bone loss / Osteoporosis

Accelerated bone mineral density decline; fracture risk ↑Friedrich 2025

Baseline DEXA scan recommended; bisphosphonates or denosumab may be indicated.

—

Metabolic syndrome

Weight gain, insulin resistance, dyslipidemia, diabetes risk

—

Sexual dysfunction

Erectile dysfunction, loss of libido (expected pharmacological effect)Jia 2025

—

Injection site reactions

Pain, erythema, sterile abscess (rare with depot formulations)

—

Gynecomastia / Breast tenderness

Common (10–20%); peripheral aromatization of residual androgens

—

Fatigue / Mood changes

Anemia, depression, cognitive changes reported in long-term ADT

—

Hepatotoxicity

Transient transaminase elevations; clinically apparent liver injury rare

—

Racial differences (ADT)

Black veterans show higher CV event rates vs White veterans on GnRH agonists

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Triptorelin

·Hypersensitivity to triptorelin, GnRH, or GnRH agonist analogues
·Pregnancy (Category X)

Vesugen

—

Relative Contraindications

Triptorelin

·Active cardiovascular disease — consider GnRH antagonist alternative
·Metastatic vertebral disease with spinal cord compression risk (flare hazard)
·Severe urinary obstruction — may worsen during flare
·Osteoporosis or high fracture risk (requires bone-protective therapy)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Triptorelin

Vesugen

1. Formulation selection

Choose 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot based on adherence needs and clinical context. 6-month formulation shows improved real-world adherence in Asia-Pacific cohorts.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

Intramuscular — gluteal or deltoid muscle. Use 21–23G needle. Aspirate to confirm non-vascular placement. Rotate sites with repeat injections.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Initial flare mitigation

For metastatic prostate cancer: co-administer antiandrogen (e.g., bicalutamide 50 mg daily) starting 1 week before first injection and continuing 2–4 weeks to prevent tumor flare.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Monitoring schedule

Baseline: testosterone, PSA, bone density (DEXA), lipids, glucose. Follow-up: testosterone at 4 weeks (confirm <50 ng/dL castration), PSA monthly × 3, then quarterly. Annual DEXA for bone loss.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Storage

Store vials at room temperature (20–25 °C), protect from light. Do not freeze. Reconstituted suspension should be used immediately.

—

6. Intermittent ADT protocol (optional)

Some protocols use on-treatment periods (9–12 months) alternating with off-treatment intervals until PSA rises. Cardiovascular risk appears similar to continuous ADT.

—

06Stack Synergy

Triptorelin

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)